EQL Pharma ABOSTO:EQL -2.32%42 Current Ratio is 1.92 as of Mar. 2026, which is 19% above its 10-year median of 1.62. GuruFocus rates OSTO:EQL with a GF Score™ of 42/100. The stock has 4 warning signs investors should review. Among 997 Drug Manufacturers companies, EQL Pharma AB ranks worse than 51.76% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. EQL Pharma AB's current ratio for the quarter that ended in Mar. 2026 was 1.92.
EQL Pharma AB has a current ratio of 1.92. It generally indicates good short-term financial strength.
The historical rank and industry rank for EQL Pharma AB's Current Ratio or its related term are showing as below:
OSTO:EQL'
s Current Ratio Range Over the Past 10 Years
Min: 1.03 Med: 1.62 Max: 6.73
Current: 1.92
During the past 13 years, EQL Pharma AB's highest Current Ratio was 6.73. The lowest was 1.03. And the median was 1.62.
OSTO:EQL's Current Ratio is ranked worse than 51.76% of 997
companies
in the Drug Manufacturers industry
Industry Median: 2
vs OSTO:EQL: 1.92
EQL Pharma AB (OSTO:EQL) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
EQL Pharma AB Current Ratio Related Terms
EQL Pharma AB Current Ratio Historical Data
* Premium members only.
The historical data trend for EQL Pharma AB's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, EQL Pharma AB's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EQL Pharma AB Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, EQL Pharma AB's Current Ratio distribution charts can be found below:
* The bar in red indicates where EQL Pharma AB's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EQL Pharma AB (OSTO:EQL) has a Current Ratio of 1.92 as of Mar. 2026. This is 19% above median its historical median of 1.62. Over the past decade, EQL Pharma AB's Current Ratio has ranged from 1.03 to 6.73. According to the industry distribution chart, EQL Pharma AB ranks #516 out of 997 companies in the Drug Manufacturers industry, placing it in the top 51.8%.
Is EQL Pharma AB's Current Ratio too high?
EQL Pharma AB's current Current Ratio of 1.92 is 19% above median its 10-year median of 1.62. Over the past 10 years, this metric has ranged from a low of 1.03 to a high of 6.73. The Drug Manufacturers industry median Current Ratio is 2.00. EQL Pharma AB's value of 1.92 is 4% below this industry median. Based on the distribution chart, EQL Pharma AB ranks #516 out of 997 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, EQL Pharma AB has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does EQL Pharma AB's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, EQL Pharma AB ranks #516 out of 997 companies for Current Ratio. This places EQL Pharma AB in the lower half of its industry. The industry median Current Ratio is 2.00. EQL Pharma AB's value of 1.92 is 4% below this benchmark. Historically, EQL Pharma AB's own Current Ratio has ranged from 1.03 to 6.73 over the past decade. While the company's 10-year median is 1.62 vs. the industry median of 2.00, EQL Pharma AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EQL Pharma AB's current Current Ratio of 1.92 is 4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EQL Pharma AB's current Current Ratio is 1.92, which is 19% above median its own 10-year median of 1.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EQL Pharma AB stock overvalued right now?
EQL Pharma AB (OSTO:EQL) has a current Current Ratio of 1.92. The current Current Ratio is 1.92, which is 19% above median its 10-year median of 1.62 and 4% below the Drug Manufacturers industry median of 2.00. EQL Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For EQL Pharma AB (OSTO:EQL), the current Current Ratio is 1.92 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.
42GF Score
Get the complete analysis for OSTO:EQL
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:EQL has been successfully added to your 
